Transparency Market Research

Hepatitis C Market Identifying Key Drivers and Issues

Transparency Market Research includes new market research report "Hepatitis C Market" to its huge collection of research reports.


Albany, NY -- (SBWIRE) -- 10/20/2014 -- The global Hepatitis C market is currently witnessing a surge in the number of people affected by the hepatitis C associated illnesses. It is still unsure as to the number of people actually infected with the virus. Despite the uncertainties, it is commonly believed that a large number of people are currently affected with the hepatitis C virus and require medical attention.

Browse the full Hepatitis C Market Report with TOC

About the Hepatitis C Virus

Hepatitis C is a highly infectious disease that affects the liver. While the infection is generally asymptomatic, a chronic infection usually leads to liver scarring and cirrhosis. Liver damage generally shows symptoms after many years due to the nature of the liver. In later stages the liver cirrhosis caused by hepatitis C will develop liver cancer, liver failure or even gastric and esophageal varices.

The hepatitis C virus is transmitted by contact between clean and infected blood. The most common methods of infection occur through unclean needles or donated blood that is not screened. The WHO has estimated that at least 3% of the global population is currently infected by the hepatitis C virus, which amounts to about 170 million people. It is also estimated that about 3 million to 4 million people in the U.S. are infected with only half of them being diagnosed.

The largest groups of people associated with the hepatitis C virus are drug users, people with tattoos, homeless people, and prisoners. This is because of the common habit of sharing unsterilized needles for drug intake and for using the same unclean tool to draw tattoos by amateur artists. This also means that a large part of those infected with hepatitis C might also be uninsured.

The Hepatitis C Market Overview

The standard drugs used for the treatment of hepatitis C are ribavirin, peginterferon, telaprevir or boceprevir. Only 50 to 80 percent of those who receive treatment are cured. Patients whose infection is severe enough to cause liver cirrhosis usually require a liver transplant. This is one of the leading factors that drive the liver transplant market as well. However, even after the patient receives a liver transplant, the chances of the infection recurring are still high. There is currently no vaccine against hepatitis C, although a number of studies and tests of drugs under development seem to show some amount of promise. The best method to remain safe from a hepatitis C infection is to promote harm reduction strategies such as providing fresh syringes and needles to hospitals in underdeveloped countries and therapeutic treatment for drug use. Most doctors in underdeveloped countries should use oral medication as often as possible to avoid using intravenous injections.

Modern Endeavors

Current strides in biotechnology have enabled drug makers to start experimenting on new chemicals. One of the target drugs that are rising in popularity is the protease inhibitor. They were earlier used to help those diagnosed positive with HIV to manage the disease instead of becoming weaker and more susceptible to death. Another drug class that showed early promise is the polymerase inhibitor. One polymerase inhibitor known as nucleotide, or more commonly known as “nucs”, is popular due to its high rate of effectiveness.

In conclusion, the hepatitis C market depends on the prime objective of providing successful treatment methods to those infected, as well as creating awareness to reduce drug use and promoting safer practices in medicine. The strategies and treatments will continue to be different in developed and developing countries, which makes room for diversity in the hepatitis C market. Identifying the needs of each market on a regional scale and applying global standards wherever relevant could provide one of the best methods of eradicating the hepatitis C virus.

Read More Reports on Pharmaceutical Market:

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Enquiry before Buying

Latest Upcoming Reports

Contact Us:

Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.

Tel: 518-618-1030

Browse All Press Releases:

Browse All Articles: